Review Article
Advances in Targeting HER3 as an Anticancer Therapy
Table 1
HER3-targeted drugs under development.
| | Drug | Type | Target(s) | Development phase | Sponsor |
| | MM-121 | Humanized mAb | HER3 | Phase I/II | Merrimack | | U3-1287 (AMG 888) | Humanized mAb | HER3 | Phase I | U3 Pharma GmbH | | MM-111 | Bispecific antibody | HER2-HER3 | Phase I | Merrimack | | Pertuzumab | Humanized mAb | HER2-HER3 | Phase III | Genentech | | MEHD7945A | mAb | HER1, HER3 | Phase II | Genentech | | MP-470 (Amuvatinib) | Pan inhibitor | HER1/2/3 | Phase II | Astex Pharmaceuticals | | AZD8931 | Pan inhibitor | HER1/2/3 | Phase I/II | AstraZeneca |
|
|
